COMMUNIQUÉS West-GlobeNewswire

BrainsWay Expands Deep TMS™ Access in Israel Following Significant Increase in Reimbursement Rates
17/04/2024
Company Announces 11th Recent System Installed in Israel, with More Expected this Year BURLINGTON, Mass. and JERUSALEM, April 17, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “ [...]
Zylö announces the creation and spinout of Atticus Pharma Inc.
17/04/2024
Atticus to focus on biopharma applications of the innovative ‘Powered by Z-pod ® ’ topical-delivery platform GREENVILLE, SC, April 17, 2024 (GLOBE NEWSWIRE) -- Zylö recently effected a spinout of Atticus Pharma Inc., [...]
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
17/04/2024
Tel Aviv, Israel / Vancouver, Canada, April 17, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of [...]
Ocean Drive Plastic Surgery Founder Dr. Alan Durkin Appointed VIO Med Spa Chief Medical Officer
17/04/2024
VERO BEACH, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- Ocean Drive Plastic Surgery, Dermatology, and MedSpa , the premier aesthetic surgery center on Florida’s Treasure Coast, today announced that dual Board-Certified [...]
Repligen to Report First Quarter 2024 Financial Results
17/04/2024
Webcast and Conference Call to Be Held Wednesday, May 1, 2024, at 8:30 a.m. ET WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first [...]
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
17/04/2024
– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease – – ATH434-201 Phase 2 Baseline Data Confirm Approach to Target Biomarkers for Slowing Disease Progression – – 12-Month [...]
Elara Caring Partners with Constant Therapy to Deliver First AI-Driven Speech-Language and Cognitive Therapy at Scale
17/04/2024
Home health provider collaborates with Constant Therapy Health to transform speech-language therapy; promises to improve patient outcomes and clinical and financial efficiencies LEXINGTON, Mass., April 17, 2024 (GLOBE [...]
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
17/04/2024
BPL-003 is Beckley Psytech’s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally. BPL-003 was shown to be safe and well-tolerated with a predictable pharmacokinetic profile [...]
Treace to Present at Bank of America Health Care Conference
17/04/2024
Wednesday, May 15, 2024, at 2:20 pm Pacific Time PONTE VEDRA, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a [...]
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase
17/04/2024
BOCA RATON, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of [...]
Tilray Brands Lights Up 420 With Music Festivals and Celebrations Across The Country
17/04/2024
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq | TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, is proud to announce a series of 420-events, [...]
Medigene to Present at Upcoming Scientific Conferences
17/04/2024
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, has been invited to present [...]
Enterome Announces Successful Completion of Phase 2 ROSALIE Study of EO2401 in Recurrent Glioblastoma
17/04/2024
EO2401, a pioneering OncoMimics™ peptide-based immunotherapy, has demonstrated rapid activation and significant expansion of existing effector memory T cells against tumor-associated driver antigens due to their strong [...]
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
17/04/2024
RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted approval for oral, once- [...]
Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan
17/04/2024
Tokyo, Japan and Cambridge, UK, 17 April 2024 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it has decided to issue new shares (“the Share [...]
Q1 2024 Revenue and Business Update
17/04/2024
MELBOURNE, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 31 March [...]
Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor
17/04/2024
Oxford, UK April 17th, 2024 . Theolytics, a biotechnology company developing next-generation oncolytic viral therapies, today announced it has successfully closed its latest financing round, raising a total of £19M ($24 [...]
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules
17/04/2024
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules Reminyl® is an established CNS brand for the symptomatic treatment of mild to moderately severe dementia of the Alzheimer [...]
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
17/04/2024
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeks The [...]

Pages